Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11670091 | 0.83 | POLB (0.40) | SLC22A12PPARATBXAS1ALDH1A1HPGD | |
| SCHEMBL3381757 | 0.83 | SLC22A12 (0.50) | SLC22A12PPARATBXAS1ALDH1A1HPGD | |
| SCHEMBL3841072 | 0.81 | SLC22A12 (0.51) | SLC22A12PPARATBXAS1 | |
| SCHEMBL9772271 | 0.81 | CES1 (0.47) | ALDH1A1HPGD | |
| SCHEMBL2821868 | 0.81 | TP53 (0.48) | SLC22A12PPARATBXAS1ALDH1A1HPGD | |
| SCHEMBL4398676 | 0.81 | PPARA (0.51) | SLC22A12PPARATBXAS1ALDH1A1PPARG | |
| SCHEMBL10570475 | 0.81 | SLC22A12 (0.57) | SLC22A12TBXAS1 | |
| SCHEMBL12824585 | 0.81 | SLC22A12 (0.51) | SLC22A12PPARATBXAS1ALDH1A1PPARG | |
| SCHEMBL14931837 | 0.81 | SLC22A12 (0.51) | SLC22A12PPARATBXAS1ALDH1A1HPGD | |
| SCHEMBL3381395 | 0.81 | CA12 (0.41) | SLC22A12PPARATBXAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57188563-A | — | — | None | — | — | JP | disclosed |
| US-20160362588-A1 | ADHESIVE COMPOSITION AND DISPLAY DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1773773-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1768954-A4 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2006002361-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006002350-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-4937264-A | HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1990-06-26 | — | — | US | disclosed |
| US-4864038-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0245003-A2 | Antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1987-11-11 | — | — | EP | disclosed |
| JP-S57188563-A | PREPARATION OF OPTICALLY ACTIVE 3-BENZOYLTHIO-2-METHYL- PROPIONIC ACID | TANABE SEIYAKU CO LTD | 1982-11-19 | — | — | JP | disclosed |
| US-4059699-A | O,O-diethyl-O-carboxamidophosphate esters and use to combat insects and mites | GULF OIL CORPORATION (US) | 1977-11-22 | — | — | US | disclosed |
| US-3994997-A | MITICIDES, INSECTICIDES | GULF OIL CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD3B1 | SLC22A12 1608/4885PPARA 893/4885TBXAS1 1809/4885 |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD3B1 | SLC22A12 1608/4885PPARA 893/4885TBXAS1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.